Abstract

Purpose: Using a standardized specimen protocol analysis, this study aimed to evaluate the resection margin status of patients who underwent resection for either distal cholangiocarcinoma (DC) or pancreatic ductal adenocarcinoma (PDAC). This allowed a precise millimetric analysis of each inked margin. Methods: From 2010 to 2018, 355 consecutively inked specimens from patients with PDAC (n = 288) or DC (n = 67) were prospectively assessed. We assessed relationships between the tumor and the following margins: transection of the pancreatic neck, bile duct, posterior surface, margin toward superior mesenteric artery, and the surface of superior mesenteric vein/portal vein groove. Resection margins were evaluated using a predefined cut-off value of 1 mm; however, clearances of 0 and 1.5 mm were also evaluated. Results: Patients with DC were mostly men (64% vs. 49%, p = 0.028), of older age (68 yo vs. 65, p = 0.033), required biliary stenting more frequently (93% vs. 77%, p < 0.01), and received less neoadjuvant treatment (p < 0.001) than patients with PDAC. The venous resection rate was higher among patients with PDAC (p = 0.028). Postoperative and 90-day mortality rates were comparable. Patients with PDAC had greater tumor size (28.6 vs. 24 mm, p = 0.01) than those with DC. The R1 resection rate was comparable between the two groups, regardless of the clearance margin. Among the three types of resection margins, a venous groove was the most frequent in both entities. In multivariate analysis, the R1 resection margin did not influence patient survival in either PDAC or DC. Conclusion: Our standardized specimen protocol analysis showed that the R1 resection rate was comparable in PDAC and DC.

Highlights

  • Patients diagnosed with either non-metastatic distal cholangiocarcinoma (DC) or pancreatic ductal adenocarcinoma (PDAC) are managed with a common therapeutic strategy

  • Several studies have shown the relevance of this specimen analysis technique [4,5], and it is currently recommended by both the Royal College of Pathologists and the Leeds Pathology Protocol that all patients requiring pancreaticoduodenectomy for carcinoma should undergo this examination

  • Patients with DC were mostly men (64% vs. 49%, p = 0.028), of older age (68 vs. 65 years, p = 0.033), required biliary stenting more frequently (93% vs. 77%, p < 0.01), and received a lower amount of neoadjuvant treatment (p < 0.001) than those with PDAC

Read more

Summary

Introduction

Patients diagnosed with either non-metastatic distal cholangiocarcinoma (DC) or pancreatic ductal adenocarcinoma (PDAC) are managed with a common therapeutic strategy. Since 2009, the Royal College of Pathologists and the Leeds Pathology Protocol [2] have provided guidelines, updated in 2019 [3], to assess margin status among patients who undergo pancreaticoduodenectomy for pancreatic head malignancies. Several studies have shown the relevance of this specimen analysis technique [4,5], and it is currently recommended by both the Royal College of Pathologists and the Leeds Pathology Protocol that all patients requiring pancreaticoduodenectomy for carcinoma should undergo this examination. This standardized specimen analysis allows consistent comparisons between series and, between pathologies. There is no report of a series study that has conducted a resection margin comparison using this protocol, in a recent cohort

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call